Cargando…
Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
One of the greatest challenges in improving prostate cancer (PCa) survival is in designing new therapies to effectively target bone metastases. PCa regulation of the bone environment has been well characterized; however, bone-targeted therapies have little impact on patient survival, demonstrating a...
Autores principales: | Johnson, Catherine S., Cook, Leah M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070788/ https://www.ncbi.nlm.nih.gov/pubmed/37025604 http://dx.doi.org/10.3389/fonc.2023.1100585 |
Ejemplares similares
-
Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer
por: McGuire, Jeremy J., et al.
Publicado: (2021) -
Bone Marrow-Derived Stem Cell Factor Regulates Prostate Cancer-Induced Shifts in Pre-Metastatic Niche Composition
por: Foster, Brittni M., et al.
Publicado: (2022) -
The surgical management of osteoid osteoma: A systematic review
por: Shu, Man, et al.
Publicado: (2022) -
Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer
por: Inaba, Koji, et al.
Publicado: (2021) -
Tumor- and Osteoblast-Derived Periostin in Prostate Cancer bone Metastases
por: Sun, Chuan-Yu, et al.
Publicado: (2022)